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ABSTRACT
Recent studies have identified large sets of genes in
embryonic stem and embryonal carcinoma cells
that are associated with the transcription factors
Sox2 and Oct-3/4. Other studies have shown that
Sox2 and Oct-3/4 work together cooperatively to
stimulate the transcription of their own genes
as well as a network of genes required for embryo-
genesis. Moreover, small changes in the levels of
Sox2:Oct-3/4 target genes alter the fate of stem
cells. Although positive feedforward and feedback
loops have been proposed to explain the activation
of these genes, little is known about the mecha-
nisms that prevent their overexpression. Here, we
demonstrate that elevating Sox2 levels inhibits the
endogenous expression of five Sox2:Oct-3/4 target
genes. In addition, we show that Sox2 repression
is dependent on the binding sites for Sox2 and
Oct-3/4. We also demonstrate that inhibition is
dependent on the C-terminus of Sox2, which
contains its transactivation domain. Finally, our
studies argue that overexpression of neither Oct-
3/4 nor Nanog broadly inhibits Sox2:Oct-3/4 target
genes. Collectively, these studies provide new
insights into the diversity of mechanisms that
control Sox2:Oct-3/4 target genes and argue
that Sox2 functions as a molecular rheostat for
the control of a key transcriptional regulatory
network.
INTRODUCTION
New technologies are providing the foundation for deci-
phering transcriptional regulatory networks that orches-
trate mammalian embryogenesis (1,2). Transcriptional
regulatory networks consist of functional interactions
between regulatory genes and a much larger set of down-
stream target genes. Downstream target genes possess
cis-regulatory regions (e.g. enhancers) able to respond to
and integrate multiple signals from regulatory genes,
many of which code for transcription factors (TFs).
Enhancers within the regulatory genes themselves allow
for more complex and precise control of the entire
network. Decoding and understanding transcriptional
regulatory networks will not only require an extensive
cataloging of TFs and the genes to which they bind, but
will also require a detailed understanding of how these
gene interactions are modulated by chromatin structure
and the expression levels of key TFs. Moreover, under-
standing interactions between key regulatory genes, which
inﬂuence the temporal and spatial expression of one
another by feedforward and feedback regulatory loops,
will provide novel insights into the cross talk between
diﬀerent transcriptional regulatory networks.
Recent eﬀorts using ChIP-Chip (1) and ChIP-PET
studies (2) have begun to identify large groups of genes in
embryonic stem (ES) cells that are associated with three
TFs, Nanog, Sox2 and Oct-3/4 (also known as Oct-3 and
Oct-4). Interest in this trio of TFs has grown considerably
with the recognition that each is essential for proper
mammalian embryogenesis, as well as the self-renewal and
pluripotency of ES cells (3–6). Intriguingly, hundreds of
genes identiﬁed in these genome-wide studies were found
to be co-occupied by two and, in many cases, by all three
TFs (1,2). Thus far, the cis-regulatory elements present
in the vast majority of these genes, which are responsible
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However, it is likely that the regulatory regions of many of
these genes possess remarkably similar DNA sequences,
which are responsible for the concerted binding of two or
all three of these TFs. In this regard, more conventional
approaches have identiﬁed a group of at least seven genes
that are regulated by closely spaced HMG and POU
motifs (referred to as an HMG/POU cassette), which bind
Sox2 and Oct-3/4, respectively. Although small sequence
diﬀerences exist between HMG/POU cassettes (7), the
consensus sequence generated has been useful in the
identiﬁcation of other genes regulated by the combined
action of Sox2 and Oct-3/4 (8,9). The importance of
HMG/POU cassettes is highlighted by the ﬁnding that
their disruption virtually eliminates enhancer function and
subsequent promoter activation of each gene (8–17). As
such, the HMG/POU cassette of each gene forms the core
of an enhancer that regulates the transcription of these
genes. In this study, we refer to genes that contain func-
tional HMG/POU cassettes as Sox2:Oct-3/4 target genes.
The network of Sox2:Oct-3/4 target genes includes
Sox2, Oct-3/4, Nanog, FGF-4, UTF1, Fbx15, Lefty1 and
many more are expected to be identiﬁed in the near future.
Each of these genes is expressed in ES cells and their
tumor-derived counterparts, embryonal carcinoma (EC)
cells. Furthermore, with the possible exception of Lefty1,
each of the genes is substantially down-regulated upon
diﬀerentiation of both ES and EC cells, due to the down-
regulation of Sox2 and Oct-3/4 (5,11,12,14,16,18–20). The
ﬁnding that Sox2 and Oct-3/4 work together cooperatively
to regulate the transcription of their own genes (15,16)
argues that Sox2 and Oct-3/4 proteins function as central
nodes in a critical transcriptional regulatory network that
controls the expression of other essential genes. As in the
cases of Sox2, Oct-3/4 and Nanog, FGF-4 is essential for
embryogenesis (3–6,21). Less is known about the remain-
ing three identiﬁed Sox2:Oct-3/4 target genes, Lefty1,
UTF1 and Fbx15. Although Lefty1 is not essential for the
earliest stages of mammalian development, disruption of
this gene causes serious defects in left–right patterning
of visceral organs (22). UTF1 may be essential for
development given that UTF1 null ES cells proliferate
more slowly when compared to their wild-type
counterparts (23). Thus far, Fbx15 is the only known
Sox2:Oct-3/4 target gene that has not yet been shown
to play a prominent role in normal development (14).
Given the importance of Sox2:Oct-3/4 target genes
during development, it is no surprise that their expres-
sion is tightly controlled. Small changes in Oct-3/4 levels
drastically alter cell fate. A 2-fold increase in Oct-3/4
levels causes ES cells to diﬀerentiate into endoderm and
mesoderm, whereas knockdown of Oct-3/4 causes ES cells
to diﬀerentiate into trophectoderm-like cells (24).
Modifying Nanog levels also alters the behavior of ES
cells. Overexpression of Nanog in mouse ES cells negates
their need for LIF (6). In contrast, knockdown of Nanog
results in the diﬀerentiation of ES cells to cells with the
properties of endoderm (6,25). Interestingly, Nanog has
been reported recently to interact with Sall4 to activate
target gene transcription, including the autoregulation of
the Nanog and Sall4 genes themselves, in a fashion similar
to Sox2 and Oct-3/4 (26). Nanog has also been shown to
function as part of a feedforward/feedback loop in
conjunction with Oct-3/4 and FoxD3 (27). Clearly, the
consequences of altering the levels of Oct-3/4 and Nanog
have provided useful insights into the developmental
potential of ES cells and EC cells. So far, much less
attention has been placed on understanding how altering
the levels of Sox2 inﬂuences cell fate. Although knock-
down of Sox2 causes ES cells to diﬀerentiate (28), there
are no reports describing how elevating Sox2 levels
inﬂuences the regulation of Sox2:Oct-3/4 target genes.
Current evidence indicates that Sox2 and Oct-3/4 work
cooperatively to stimulate the transcription of a number of
critical genes (8–17). Given the need to tightly control the
expression of these genes, one would expect that negative
feedback loops exist to ensure that the levels of these genes
are controlled properly. Earlier work suggested that this
may be the case for FGF-4. Although it is well known that
Sox2 and Oct-3/4 work in concert to stimulate FGF-4
transcription (10,11,29,30), overexpression of Sox2 has
also been shown to inhibit the function of the FGF-4
enhancer in promoter/reporter gene constructs (31).
In this study, we have examined the possibility that
overexpression of Sox2 exerts a much broader
eﬀect over Sox2:Oct-3/4 target genes. We determined
that overexpression of Sox2 inhibits the activities of Sox2,
FGF-4, Nanog, UTF1 and Oct-3/4 promoter/reporter
gene constructs in both EC cells and ES cells. Importantly,
we determined that overexpression of Sox2 in F9 EC cells
inhibits the endogenous expression of ﬁve Sox2:Oct-3/4
target genes, Sox2, FGF-4, Nanog, UTF1 and Oct-3/4.
Fbx15 and Lefty1 were not examined in this study.
We also determined that this eﬀect is mediated through
the HMG/POU cassettes in the enhancers of these genes.
Moreover, we demonstrate that the eﬀect of Sox2 is
mediated by its C-terminal region, which contains its
transactivation domain (TAD). Finally, we show that
although overexpression of Oct-3/4 and Nanog each
inhibits its own promoter, their overexpression does
not appear to broadly inhibit the promoters of other
Sox2:Oct-3/4 target genes.
MATERIALS AND METHODS
Cell cultureconditions
Stock cultures of mouse F9 EC cells and P19 EC cells were
maintained in Dulbecco’s modiﬁed Eagle’s medium (Life
Technologies, Inc.) supplemented with 10% fetal bovine
serum (HyClone, Logan UT) as reported previously (32).
D3 ES cells were cultured in the absence of a feeder
layer in medium supplemented with leukemia-inhibiting
factor as described previously (29). Stock cultures and all
experimental cultures were maintained at 378C in a moist
atmosphere of 95% air and 5% CO2.
Transient transfection assays
F9 EC cells and P19 EC cells were seeded at 500000
cells per 100-mm dish and transfected in duplicate the
following day using the calcium phosphate precipitation
method as described previously (29). In addition to 12mg
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co-transfected with 1mg of the internal standard pCMV-
b-gal (Clontech, Palo Alto, CA, USA) to normalize for
any diﬀerences in transfection eﬃciency. Where indicated,
either 1 or 3mg of a CMV-driven expression vector was
co-transfected with the promoter/reporter construct.
D3 ES cells were seeded at 150000 cells per 60-mm dish
and transfected in duplicate the following day using
Lipofectamine
TM 2000 Transfection Reagent (Invitrogen,
Carlsbad, CA, USA), as described previously (33), using
4.5mg of promoter/reporter construct and 1mg of pCMV-
b-gal. Where indicated, 0.3 or 1.0mg of the Sox2 expres-
sion vector was co-transfected. For all transfections, DNA
from the empty vector, CMV5, was added where needed
to ensure that all cells were transfected with the same
amount of DNA. Calcium phosphate transfected cells
were washed twice 24h after transfection with serum-free
medium and refed with serum-containing medium. With
all transfections, chloramphenicol acetyltransferase (CAT)
and b-galactosidase activities were determined 48h after
transfection as described previously (29).
Plasmid constructs
The plasmid construct FGF-4þE (previously named
427TþE) contains 427bp of the mouse FGF-4 promoter
and 316bp of the mouse FGF-4 enhancer separated
by a CAT reporter gene (29,34,35). The construct
FGF-4þE(HPmut), previously named 427TþEnGSp,
is similar to FGF-4þE except that the HMG/POU
cassette has been replaced with a binding site for the
DNA-binding domain (DBD) of the yeast TF GAL4 (13).
The construct NanogþE contains the mouse Nanog
promoter and enhancer cloned directly upstream of the
CAT reporter gene. The region from  812 to þ171 of the
Nanog transcription start site was PCR ampliﬁed from
mouse genomic DNA using the following primers:
50-cgtgatGTCGACAATTTCTTCTTCCATTGCTTAGA
CGG-30 and 50-tgcAGATCTAAGGGATTTCTGAAA
AGGTTTTAGGC-30. The SalI and BglII restriction
sites shown in italics and a small piece of extra DNA
shown in lowercase allow for restriction enzyme digestion
and cloning of the fragment containing the Nanog
promoter and enhancer into the previously described
pBLCAT7 reporter plasmid (35).
The construct UTF1þE was described previously (7)
and contains 321bp of the mouse UTF1 promoter
( 202 to þ119) (12,36) cloned upstream of the CAT
reporter gene as well as 139bp of the mouse UTF1
enhancer (12) cloned downstream of the CAT reporter
gene. The construct UTF1þE(HPmut) was created
from UTF1þE by replacing the HMG/POU cassette
with a DNA sequence able to bind the DBD of the
yeast TF GAL4. This change was made by the cassette
exchange method (7), using the following primers:
50-tggaAGATCTCGGAGGACAGTCCACCGACGGCT
CATCCTGAGGCTC-30 and 50-tggaAGATCTCCGGC
AGCAGCTTCCTTTCC-30 where the GAL4 site is
underlined, the BglII sites are in italics, and a small
piece of extra DNA is in lowercase (to facilitate restriction
enzyme digestion).
The Oct-3/4 promoter and enhancer elements were
also ampliﬁed from mouse genomic DNA and cloned
into pBLCAT7 upstream of the CAT reporter gene
to create Oct-3/4þE using the following primers:
50-ttctGTCGACTCTAGGCACGCTTAGGGC-30 and
50-ttctAGATCTCCGAGCCGGGGGCCTGGTGG-30
(SalI and BglII sites in italics and extra bases in lower-
case). This ampliﬁed a fragment spanning  2295 to þ33
of the Oct-3/4 gene, which includes the promoter and both
the proximal and distal enhancer (16,37). The construct
Sox2þUS/DSE contains the Sox2 promoter and CAT
reporter gene as well an upstream Sox2 enhancer element
and a downstream Sox2 enhancer element (containing the
HMG/POU cassette), all placed relative to their natural
positions. The mouse Sox2 promoter was described
previously (38) and consists of the  528 to þ238 region
(relative to the transcription start site). The upstream Sox2
enhancer was cloned from genomic mouse DNA with
the following primers: 50-cctcCATATGTCAAATAGGG
CCCTTTTCAG-30 and 50-cctcCATATGAAGCCAACT
GACAATGTTGTGG-30 (NdeI sites in italics and extra
bases in lowercase), which amplify a 392bp fragment
 4kb upstream of the Sox2 transcription start site
previously described as the ‘0.4a’ Sox2 enhancer
region (39). The downstream Sox2 enhancer (containing
the HMG/POU cassette) was cloned with the following
primers: 50-catGAGCTCGGTTCCCCTCTAATTAATG
CAGAGAC-30 and 50-catGAGCTCATACTGTCCATT
GGCTGGAGTTCC-30 (SacI sites in italics and extra
bases in lowercase), which amplify a 211bp region  2kb
downstream of the Sox2 gene. The construct Sox2þ
US/DSE(HPmut) contains the GAL4-binding site in
place of the HMG/POU cassette. It was generated by
the cassette exchange method, using the following primers:
50-ggaAGATCTCGGAGGACAGTCCACCGAGGATT
ATTCACGTGGTAATGAGC-30 and 50-tggaAGATCT
TGCCCGAGCCCGGGAAATTCTTTTAGAG-30 where
the GAL4 site is underlined, the BglII sites are in italics,
and a small piece of extra DNA is in lowercase. Site-
directed mutagenesis was used to destroy the POU motif
of the Sox2þUS/DSE construct, creating Sox2þ
US/DSE(Pmut), using the following primers: 50-CCC
GGGCTCGGGCAGCCATTGTGgccggcATAGGATTA
TTCACG-30 and 50-CGTGAATAATCCTATgccggcCA
CAATGGCTGCCCGAGCCCGGG-30 where a new
NaeI site (italics) was introduced in place of the POU
motif (underlined). Changes from wild-type sequence are
shown in lowercase.
The contruct TK contains the herpes simplex virus
(HSV) thymidine kinase (TK) promoter cloned upstream
of the CAT reporter gene. TKþE contains the HSV TK
promoter plus the FGF-4 enhancer (as in FGF-4þE)
downstream of the CAT reporter gene. Both constructs
were described previously (13).
All expression vectors are driven by the CMV promoter.
CMV-Sox2 contains a cDNA for the entire coding region
of mouse Sox2, as described previously (30). Likewise,
CMV-Oct-3/4 contains the coding region of mouse
Oct-3/4, as described previously (30). The expression
vector CMV-Sox11 and the chimeras CMV-Sox2-2-11
(Sox2 HMG/DBD domain with Sox11 TAD) and
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TAD) were also described previously (40). The empty
expression vector GFP is also known as pEGFP-C1
(Clontech). GFP-Sox2 is a fusion of GFP and the
full-length Sox2 cDNA and was described previously (30).
The CMV-Nanog expression vector contains the full-
length mouse Nanog cDNA (1.0kb) ampliﬁed from
F9 EC cell RNA with the following primers:
50-cctcAAGCTTTTCAGAAATCCCTTCCCTCGCC-30
and 50-ctccTCTAGAAGGAAGGAACCTGGCTTTG
CCC-30 where HindIII and XbaI restriction sites are
shown in italics (extra DNA for restriction enzyme
digestion in lowercase) allowing for cloning into the
CMV expression vector.
GFP transfection andcell sorting
F9 EC cells were seeded at 500000 cells per 100-mm dish
and transfected using Lipofectamine 2000 Reagent
TM,a s
described previously (33). In short, after 24h, each plate
was transfected with either 3mg empty GFP vector or 3mg
GFP-Sox2. After an additional 24h, cells were prepared
for sorting as follows. Each plate was washed two times
with 5ml of PBS. Cells were then trypsinized, collected
in serum-containing medium and transferred to 1.5ml
Eppendorf tubes before being spun down at 48C and
3000 r.p.m. for 5min. The resulting cell pellet was
resuspended in 1ml of serum-containing medium per
plate and GFP positive cells were sorted and collected
in the UNMC Cell Analysis Facility using a BD
FACSAria
TM Flow Cytometer (San Jose, CA, USA).
Data was acquired and analyzed with DiVa 5.0.1 software.
RNA isolation andcDNA synthesis
GFP positive cells were obtained, spun down and
resuspended in 800ml TRIzol Reagent (Invitrogen).
RNA was isolated according to the manufacturer’s
protocol with the exception of increasing the precipitation
step to overnight at  208C. RNA pellets were resuspended
in 20ml RNase/DNase-free H2O. The concentration of
RNA was determined by UV spectrophotometry. RNA
was treated with ampliﬁcation grade DNase I (Invitrogen).
Next, cDNA was synthesized using the SuperScript
III First-Strand Synthesis SuperMix (Invitrogen).
Quantitative PCR
The cDNA generated from GFP and GFP-Sox2 trans-
fected cell isolates was subjected to SYBR green qPCR on
the Cepheid SmartCycler using software Version 2.0c
(Sunnyvale, CA, USA). Gene expression was assayed
using RT2 Real-Time
TM SYBR Green PCR master mix
from SuperArray BioScience Corporation (Frederick,
MD, USA) according to the manufacturer’s protocol
using the following gene-speciﬁc primers. Primer sets
speciﬁc for mouse GAPDH (PPM02946A), FGF-4
(PPM03044A), UTF1 (PPM04713A), Oct-3/4 (also
known as Pou5f1, PPM04726A) and Sox2 (PPM04762A)
were obtained from SuperArray, with the catalog numbers
shown in parentheses. The Sox2 primer was used to detect
overexpression of GFP-Sox2. Nanog-speciﬁc primer
sequences were obtained from PrimerBank, Nanog pair
3 (PrimerBank ID 31338864a3): upper 50-CCTGATTCTT
CTACCAGTCCCA-30 and lower 50-GGCCTGAGAGA
ACACAGTCC-30; which create a 123bp amplicon (41).
Endogenous Sox2 gene expression was detected using a
primer set speciﬁc for a portion of the Sox2 50 untranslated
region (not present in the expression plasmid). The
primers, upper 50-AAGGAGAGAAGTTTGGAGCC-30
and lower 50-TCTGGCGGAGAATAGTTGG-30 create
a 153bp amplicon. Relative gene expression for each
transfection (GFP and GFP-Sox2) was calculated accord-
ing to the SuperArray protocol and normalized
to GAPDH. Gene expression for GFP-Sox2 transfected
cells was reported as a fraction of the corresponding
expression in control (GFP transfected) cells.
Western blot analysis
F9 EC cells were transfected with GFP-Sox2 and
subjected to sorting as described above. Nuclear extracts
were prepared from GFP-positive cells using the
NE-PER
TM nuclear and cytoplasmic extraction kit
(Pierce, Rockford, IL, USA). Nuclear extracts were
prepared in the presence of protease inhibitors: aprotinin
(2.5 kallikrein-inactivating U/ml), PMSF (0.2mM),
soybean trypsin inhibitor (20mg/ml), pepstatin A
(1mg/ml) and leupeptin (1mg/ml) (42). Nuclear extracts
also contained the protein phosphatase inhibitor NaF
(5mM) and NaPPi (30mM). The resultant nuclear extract
was separated on a 4–20% SDS PAGE gel and then
transferred to an Immobilon-P PDVF membrane
(Millipore, Bedford, MA, USA). Western blot analysis
was performed using the Chemicon International, Inc.
(Temecula, CA, USA) anti-Sox2 antibody (AB5603) at
a1 mg/ml concentration and an alkaline phosphatase
conjugated goat a-rabbit secondary antibody (1:1000).
Sox2 migrated as a  35kDa protein [as described
previously, (7)] and GFP-Sox2 migrated at  60kDa
(due to the  25kDa GFP epitope). Proteins were detected
using an enhanced chemiﬂourescence kit (Amersham
Biosciences) and scanned on a Storm PhosphorImager
and quantiﬁed using ImageQuant analysis software
(Molecular Dynamics, Sunnyvale, CA).
RESULTS
Overexpression ofSox2results in inhibition ofSox2
promoter activity
Recent work has shown that Sox2 is critical for the
expression of a network of Sox2:Oct-3/4 target genes.
However, since Sox2 contributes to the activation of its
own transcription, it was unclear whether mechanisms
exist to prevent the overexpression of Sox2 and other
Sox2:Oct-3/4 target genes. To test this possibility, we
examined the eﬀects of Sox2 overexpression in F9 EC
cells. F9 EC cells were chosen because they have been used
extensively to study the expression of Sox2:Oct-3/4 target
genes (43). These cells not only express the same set of
Sox2:Oct-3/4 target genes as ES cells, the expression of
these genes turns oﬀ at the transcriptional level when ES
cells and F9 EC cells diﬀerentiate (5,11,12,14,16,18–20).
In our initial studies, F9 EC cells were transiently
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promoter/reporter gene construct. The Sox2 promoter/
reporter gene construct used for these studies contains the
two enhancers known to be functional in EC and ES cells
(15,39). One enhancer is located  4kb upstream of the
Sox2 transcription start site and the second, which
contains the HMG/POU cassette, is located  2kb down-
stream of the single exon of Sox2. In our promoter/
reporter gene construct, the placement of the two Sox2
enhancers reﬂects their position in the endogenous Sox2
gene (Figure 1A). We determined that Sox2 overexpres-
sion inhibited the activity of our Sox2 promoter/enhancer
gene construct in a dose-dependent manner (Figure 1A).
In contrast, another Sox family member, Sox11, which has
a DBD that exhibits nearly 70% sequence identity with
Sox2 (40), had no eﬀect on promoter/reporter activity
when overexpressed in F9 EC cells (Figure 1B). Moreover,
overexpression of neither Oct-3/4 (Figure 1A and B) nor
Nanog (see below) inhibited the activity of the Sox2
promoter/enhancer gene construct.
Sox2overexpression inhibits thepromoter of multiple
Sox2:Oct-3/4 targetgenes
Given the eﬀect of Sox2 overexpression on its own
promoter/reporter gene construct, we tested whether
Sox2 exerted similar eﬀects on other Sox2:Oct-3/4 target
genes. Using a panel of promoter/reporter constructs, we
determined that Sox2 overexpression inhibited the activity
of FGF-4, Oct-3/4, Nanog and UTF1 promoter/reporter
gene constructs in a dose-dependent fashion (Figure 2).
Each of the promoter/reporter gene constructs contained
the appropriate promoter and enhancer regions, including
a functional HMG/POU cassette within their respective
enhancers. Furthermore, the placement of the enhancers
within the promoter/reporter gene constructs reﬂects their
positions, relative to the transcription start site, in their
endogenous genes (see Materials and methods section for
details). Remarkably, each promoter/enhancer construct
exhibited a similar dose-dependent inhibition in response
to Sox2 overexpression, which suggests that a common
mechanism may be responsible for the inhibition of each
promoter/reporter gene construct. Interestingly, the resid-
ual activity observed in response to Sox2 overexpression
was greater than the activity of equivalent constructs in
which the HMG/POU cassette was disrupted, which is
typically 490% lower than the activity of the wild-type
promoter/reporter gene construct (8,11–13,15–17,44).
We considered the possibility that high levels of Sox2
lead to a reduction in the levels of Oct-3/4, and, as a result,
cause a reduction in the expression of all Sox2:Oct-3/4
target genes. We tested this possibility by examining
whether the inhibition by Sox2 could be reversed
by overexpressing Oct-3/4. However, in combination
with Sox2, Oct-3/4 overexpression did not reverse the
inhibition observed with Sox2 overexpression (Figure 3).
Interestingly, overexpression of Oct-3/4 on its own
increased the activities of both the Sox2 and the FGF-4
promoter/reporter gene constructs (Figure 3). Moreover,
as shown below, overexpression of Oct-3/4 in the absence
of Sox2 substantially inhibits the activity of the
Oct-3/4 promoter/reporter gene construct. Hence, down-
regulation of Oct-3/4 does not appear to be primarily
responsible for the eﬀects of Sox2 overexpression.
Sox2overexpression inhibits the expression of endogenous
Sox2:Oct-3/4target genes
Given the broad eﬀects of Sox2 overexpression observed
above, we examined the eﬀects of Sox2 overexpression on
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Figure 1. Eﬀect of Sox2 Oct-3/4 and Sox11 overexpression on Sox2
promoter activity. Schematic of the Sox2 promoter/reporter construct is
shown. The gray boxes indicate critical enhancers, the basal Sox2
promoter is represented by a black box adjacent to the CAT reporter
gene, and the relative HMG/POU cassette is indicated with an asterisk.
F9 EC cells were transiently transfected and assayed as described in the
Materials and methods section. The cells were transfected with 12mgo f
the Sox2 promoter/reporter gene construct (Sox2þUS/DSE) plus 1mg
of the CMV-b-gal expression vector. In (A), 1 or 3mg of either the
Sox2 or Oct-3/4 expression vector was co-transfected. In (B),3 mg
of the indicated expression vector (Sox2, Oct-3/4 or Sox11)
was co-transfected. Reporter activity was normalized to that of
b-galactosidase and the activity of Sox2þUS/DSE (with no over-
expression) was set to 1. The data shown represents the mean
and standard deviation of duplicate samples from a representative
experiment. Each experiment was repeated twice and similar results
were obtained.
Nucleic Acids Research, 2007, Vol. 35, No. 6 1777the endogenous expression of Sox2:Oct-3/4 target genes.
For this purpose, we used a chimeric protein containing
GFP fused to full-length Sox2 (GFP-Sox2), which like
Sox2, inhibits the activities of constructs containing
promoter/enhancer regions of Sox2:Oct-3/4 target genes
(data not shown). More speciﬁcally, F9 EC cells were
transiently transfected with either an expression vector for
GFP (control) or an expression vector for GFP-Sox2. One
day later, GFP positive cells for each condition were
collected by cell sorting and their RNA isolated and
analyzed by real-time qPCR using GAPDH expression for
normalization (Figure 4A). Consistent with the results
described above, we determined that mRNA for FGF-4,
Oct-3/4, UTF1 and Nanog were each reduced by  50% in
cells transfected with GFP-Sox2. Using a primer set
that detects a region of Sox2 mRNA not present in the
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Figure 2. Eﬀect of Sox2 overexpression on multiple Sox2:Oct-3/4 target
gene promoters. Schematics of each of the promoter/reporter constructs
are shown. The gray boxes indicate critical enhancers, the basal
promoter is represented by a black box adjacent to the CAT reporter
gene, and the relative HMG/POU cassette is indicated with an asterisk.
F9 EC cells were transfected with 12mg of the indicated promoter/
reporter gene construct plus 1mg of the CMV-b-gal expression vector.
Where indicated, 1 or 3mg of the Sox2 expression vector was
co-transfected. Reporter activity was normalized to that of
b-galactosidase and the activity of each individual promoter/reporter
construct (with no Sox2 overexpression) was set to 1. Overexpression
values are shown relative to each particular gene construct. The
data shown represents the mean and standard deviation of duplicate
samples from a representative experiment. This experiment was
repeated twice and similar results were obtained.
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Figure 3. Eﬀect of Sox2 plus Oct-3/4 overexpression on the Sox2 and
FGF-4 promoters. Schematics of each of the promoter/reporter
constructs are shown. The gray boxes indicate critical enhancers, the
basal promoter is represented by a black box adjacent to the CAT
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from representative experiments. Each experiment was repeated twice
and similar results were obtained.
1778 Nucleic Acids Research, 2007, Vol. 35, No. 6GFP-Sox2 expression vector, we detected a reduction
(averaging 30%) of endogenous Sox2 gene expression.
We suspect there are several reasons why the reduction
in endogenous gene expression ( 50%) was less than that
seen in the promoter/reporter gene assays ( 80%).
The most likely explanation is the diﬀerence in time
courses used in the two assays, 24 and 48h, respectively.
In addition, diﬀerent endpoints were assayed—mRNA as
opposed to CAT enzymatic activity. To examine the level
of GFP-Sox2 protein in the transfected cells, GFP-Sox2
positive cells were isolated 24h later. Western blot analysis
was performed on nuclear extracts prepared from
the isolated cells using a Sox2 antibody. This antibody
detects both endogenously expressed Sox2 and the larger
GFP-Sox2 fusion protein and the relative intensities of
Sox2 and GFP-Sox2 were measured as described in the
Materials and methods section. We determined that
GFP-Sox2 levels were  2-fold higher than endogenously
produced Sox2 (Figure 4B). If the levels of endogenous
Sox2 have not changed signiﬁcantly, and may have
actually decreased in response to GFP-Sox2, then the
combined level of Sox2 and GFP-Sox2 in the transfected
cells was at most 3-fold higher than the normal levels
of Sox2. In related studies, we determined that the
viability of the F9 EC cells was not compromised by
overexpression of Sox2. When replated after cell sorting,
the plating eﬃciency and morphology of the GFP and the
GFP-Sox2 cells were very similar to one another and to
that of untreated F9 EC cells (data not shown). Taken
together, our ﬁndings argue that Sox2 overexpression not
only inhibits the activity of promoter/reporter constructs
of Sox2:Oct-3/4 target genes, but also inhibits the
expression of their endogenous counterparts.
Sox2inhibition is mediated through afunctional
HMG/POU cassette
Next, we examined the underlying mechanism(s) respon-
sible for the inhibitory eﬀects of Sox2. The ﬁnding that
each of the ﬁve promoter/reporter constructs was inhib-
ited to a similar extent by Sox2 overexpression raised the
possibility that the inhibitory eﬀects of Sox2 are mediated
by a common mechanism. A common denominator
among each of the ﬁve genes is the presence of an
HMG/POU cassette in a critical enhancer present in each
of the genes. The involvement of HMG/POU cassettes is
consistent with our previous ﬁnding that Sox2 over-
expression does not inhibit the FGF-4 promoter in
constructs lacking the FGF-4 enhancer nor does it inhibit
an FGF-4 promoter/reporter gene construct in which
the HMG/POU cassette of the FGF-4 enhancer is
disrupted (31). Similarly, Sox2 overexpression does not
inhibit the activity of a promoter/reporter construct
containing the Sox2 promoter, but lacking the Sox2
enhancers (data not shown).
To examine the role of the HMG/POU cassettes
of these genes, we initially tested the eﬀects of Sox2
overexpression on the activity of a heterologous promoter/
reporter construct pCATSO3, which contains six copies of
the FGF-4 HMG/POU cassette upstream of a minimal
SV40 promoter (30). As in the case of the ﬁve promoter/
reporter gene constructs tested above (Figures 1 and 2),
Sox2 overexpression caused a dose-dependent decrease in
the activity of pCATSO3 in F9 EC cells (data not shown).
Next, we compared the eﬀects of Sox2 overexpression on
a panel of promoter/reporter constructs for the Sox2,
UTF1 and FGF-4 genes in which the HMG/POU cassette
present in each of their enhancers had been disrupted by
0
0.5
1.0
G
F
P
-
S
o
x
2
/
c
o
n
t
r
o
l
Nanog
UTF1
Oct-3/4
FGF-4
** P<0.02
* P<0.05
Sox2
B A
GFP-Sox2
Sox2 35
50
75
Figure 4. Eﬀect of Sox2 overexpression on endogenous Sox2:Oct-3/4 target gene expression. (A) F9 EC cells were transfected with either GFP
or GFP-Sox2, and GFP positive cells were collected and processed as described in the Materials and methods section. Between these two cell
populations, the levels of expression of ﬁve genes were compared after normalizing the values to the expression of GAPDH. Target gene expression
in GFP-Sox2-transfected cells is reported as a fraction of the corresponding expression in control cells (GFP-transfected). The values shown represent
the mean and standard deviation after averaging values from two separate isolates of GFP positive cells and at least two qPCR assays of each gene.
(B) Western blot analysis of Sox2 protein in F9 EC cells transfected with the GFP-Sox2 expression plasmid and collected by ﬂow cytometry.
GFP-Sox2 and endogenous Sox2 are indicated.
Nucleic Acids Research, 2007, Vol. 35, No. 6 1779site-directed mutagenesis. As discussed above, disruption
of the HMG/POU cassettes of these constructs reduces
their activity  90%. In contrast to the eﬀects of Sox2 on
the wild-type constructs, Sox2 overexpression did not
inhibit the activity of constructs with ablated HMG/POU
cassettes (Figure 5A). Thus, it appears that the inhibitory
eﬀects of Sox2 are mediated through the HMG/POU
cassette of Sox2:Oct-3/4 target genes. Surprisingly, Sox2
overexpression actually increased the activities of the
modiﬁed promoter/reporter gene constructs and this was
also true for a Nanog promoter/reporter gene construct in
which its HMG/POU cassette had been disrupted (data
not shown). Currently, it is unclear why Sox2 stimulates
the mutant promoter/reporter genes constructs. Possible
explanations are addressed in the Discussion section.
The synergism between Sox2 and Oct-3/4, when
bound to the HMG/POU cassettes, is well established
(7,8,10–12,14–17,28,30). Hence, we considered the
possibility that only the HMG motif, which binds Sox2,
is necessary for inhibition by Sox2 overexpression. This
possibility was tested by transfecting increasing amounts
of Sox2 in conjunction with a Sox2 promoter/reporter
construct containing a mutated POU motif, but a
functional HMG motif [Sox2þUS/DSE(Pmut)].
However, Sox2 overexpression had no inhibitory eﬀect,
and actually stimulated promoter activity, similar to that
seen when the entire HMG/POU cassette was disrupted
(Figure 5B). Hence, it appears that the HMG portion of
these cassettes, on its own, is not suﬃcient for repression
via elevated levels of Sox2, and that an intact HMG/POU
cassette is required.
The requirement for a functional HMG/POU cassette
suggested that Sox2 overexpression does not exert a
general eﬀect on transcription. This is consistent with a
lack of an inhibitory eﬀect of Sox2 on other promoters. In
addition to not observing any inhibitory eﬀects of Sox2
overexpression on the FGF-4 and Sox2 promoters (in the
absence of their respective enhancers), we did not observe
any eﬀects of Sox2 overexpression on the CMV and SV40
promoters (data not shown). Similarly, Sox2 overexpres-
sion had no eﬀect on the HSV TK promoter (Figure 6).
However, when the HSV TK promoter was coupled with
the FGF-4 enhancer, which contains an HMG/POU
cassette, promoter/reporter activity was signiﬁcantly
repressed by the elevated levels of Sox2 (Figure 6).
Taken together, our ﬁndings argue that Sox2 overexpres-
sion does not exert a general eﬀect on transcription, but
rather inﬂuences the function of strong enhancers that
contain HMG/POU cassettes.
Sox2inhibition is mediated by its TAD
We also examined which domain of Sox2 is responsible for
mediating repression. For these studies, we used chimeric
proteins containing diﬀerent domains of Sox2 and
Sox11 (40). Sox2 and Sox11 each have an N-terminal
DBD (HMG domain), which share nearly 70% sequence
homology. In contrast, their C-terminal domains, which
contain their TADs, exhibit no signiﬁcant homology.
Although Sox11 inhibits the FGF-4 promoter/reporter
gene construct (31), it does not inhibit the activity of the
Sox2 promoter/reporter gene construct (Figure 1B) or
the activity of the Nanog promoter/reporter gene con-
struct (see below). This enabled us to test whether the
HMG domain and/or the C-terminal domain of Sox2 is
responsible for its inhibitory eﬀects. Speciﬁcally, we tested
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Figure 5. Eﬀect of Sox2 overexpression on Sox2:Oct-3/4 target gene
constructs containing mutant HMG/POU cassettes. Schematics of each
of the promoter/reporter constructs are shown. The gray boxes indicate
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F9 EC cells were transfected with 12mg of the indicated promoter/
reporter gene construct plus 1mg of the CMV-b-gal expression vector.
Where indicated, 1 or 3mg of the Sox2 expression vector was
co-transfected. Reporter activity was normalized to that of
b-galactosidase and the activity of each individual promoter/reporter
construct (with no overexpression) was set to 1. Overexpression values
are shown relative to each particular gene construct. The data shown
represents the mean and standard deviation of duplicate samples from
representative experiments. This experiment was repeated twice and
similar results were obtained.
1780 Nucleic Acids Research, 2007, Vol. 35, No. 6two chimeric constructs. One contained the N-terminal
region as well as the DBD of Sox2 coupled to the
Sox11C-terminal domain (Sox2-2-11). The other con-
tained the N-terminal domain and the DBD of Sox11
coupled to the Sox2C-terminal domain (Sox11-11-2)
(Figure 7A). When overexpressed in conjunction with
either a Sox2 or a Nanog promoter/reporter construct in
F9 EC cells, Sox11-11-2 and Sox2 were equally inhibitory,
whereas Sox2-2-11 stimulated both promoters (Figures 7B
and C). These results argue strongly that the C-terminal
domain of Sox2 contained in Sox11-11-2 (Sox2 amino
acids 131–319), is suﬃcient for full inhibition. Given that
the Sox2 TAD is spread over amino acids 152–189 and
255–319 (30,45), our ﬁndings further suggest that the
TAD of Sox2 is responsible for its inhibitory eﬀect. Con-
sistent with this possibility, overexpression of a truncated
form of Sox2, which lacks amino acids 292–319, did not
inhibit promoter activity (data not shown). In this regard,
we previously demonstrated that the ability of this
truncated protein to transactivate was abrogated (30).
Surprisingly, Sox2-2-11 stimulated both the Sox2 and the
Nanog promoter/reporter gene constructs. We suspect
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Nucleic Acids Research, 2007, Vol. 35, No. 6 1781that this is due to the fact that the Sox11 TAD in Sox2-
2-11 is far stronger than the TAD of Sox2 (40) and that
Sox2 and Sox11 are likely to mediate their eﬀects on
transcription through the action of diﬀerent co-activators.
Sox2overexpression inhibits Sox2:Oct-3/4 target genesin
P19 ECcells and D3ES cells
To extend the ﬁndings with F9 EC cells, the eﬀects of Sox2
overexpression were examined in mouse P19 EC cells.
Like F9 EC cells, P19 EC cells are frequently used in gene
expression studies. For these studies, P19 EC cells were
transiently transfected with a panel of Sox2:Oct-3/4 target
gene promoter/reporter constructs and increasing
amounts of a Sox2 expression vector. As in the case of
F9 EC cells, Sox2 overexpression signiﬁcantly inhibited
the activities of the Sox2, FGF-4, Nanog, UTF1 and
Oct-3/4 promoter/reporter gene constructs (Figure 8A).
The levels of inhibition of the Nanog, UTF1 and Oct-3/4
promoter/reporter gene constructs were similar to those
observed in F9 EC cells. However, the activity of the
FGF-4 promoter/reporter construct was not inhibited
as strongly as that observed in F9 EC cells. This is likely to
be due to the FGF-4 enhancer, which contains an HMG/
POU cassette, having much lower overall activity in P19
EC cells (7). To extend these ﬁndings further, mouse D3
ES cells were transiently transfected with a Sox2 expres-
sion vector and promoter/reporter gene constructs for the
Sox2, FGF-4, Nanog, UTF1 and Oct-3/4. Similar to F9
and P19 EC cells, overexpression of Sox2 caused
signiﬁcant inhibition of the Sox2, FGF-4, Nanog, UTF1
and Oct-3/4 promoter/reporter gene constructs in ES cells
(Figure 8B). Hence, the ﬁndings with P19 EC cells and D3
ES cells argue that Sox2 inhibition of Sox2:Oct-3/4 target
genes is not cell-line speciﬁc.
Neither Oct-3/4 nor Nanog broadlyinhibit thepromoters
ofSox2:Oct-3/4 target genes
Recent studies employing ChIP-Chip and ChIP-PET
technologies have shown that Sox2, Oct-3/4 and Nanog
are each associated with the regulatory regions of a large
number of genes (1,2). In many instances, two or all three
of these TFs are associated in close proximity within the
same region of the gene. Hence, it has been argued that
Sox2, Oct-3/4 and Nanog function as master regulators
that exert a strong inﬂuence over a vast array of
target genes. Given these ﬁndings, we examined whether
overexpression of Oct-3/4 or Nanog also exert broad
eﬀects over the expression of Sox2:Oct-3/4 target genes.
As discussed above, Oct-3/4 did not inhibit the activity of
the Sox2 or the FGF-4 promoter/reporter gene constructs
(Figures 3A and B). Thus, we tested the eﬀect of
overexpressing Oct-3/4 on an Oct-3/4 promoter/reporter
construct. Increasing levels of Oct-3/4 inhibited its own
promoter in a fashion similar to Sox2 overexpression
(Figure 9A). Moreover, overexpression of Oct-3/4 also
inhibited the activity of the Nanog promoter/reporter gene
construct (data not shown), as reported by others working
with ES cells (27). We also determined that overexpression
of Nanog inhibited the activity of the Nanog promoter/
reporter gene construct. However, Nanog overexpression
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Figure 8. Eﬀect of Sox2 overexpression on Sox2:Oct-3/4 target genes in
P19 EC cells and D3 ES cells. (A) Eﬀects of Sox2 overexpression on Sox2,
FGF-4, Nanog, UTF1 and Oct-3/4 promoter/reporter gene constructs in
P19 EC cells. (B) Eﬀects of Sox2 overexpression on Sox2, FGF-4, Nanog
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the cells were also transfected with 0.3 or 1mg of the Sox2 expression
vector. In both (A) and (B), reporter activity was normalized to that of
b-galactosidase and the activity of each individual promoter/reporter
construct (with no Sox2 overexpression) was set to 1. Overexpression
values are shown relative to each particular gene construct. The data
shown represents the mean and standard deviation of duplicate samples
from a representative experiment. Each experiment was repeated and
similar results were obtained.
1782 Nucleic Acids Research, 2007, Vol. 35, No. 6exerted little or no eﬀect over the Oct-3/4 promoter/
reporter gene construct (Figure 9A) or the Sox2 promoter/
reporter gene construct (Figure 9B). Collectively, our
results argue that Sox2 overexpression exerts an over-
arching eﬀect over Sox2:Oct-3/4 target genes; whereas,
overexpression of Oct-3/4 and Nanog exert more
restricted eﬀects over Sox2:Oct-3/4 target genes.
DISCUSSION
Recent studies argue that Sox2 and Oct-3/4 work in
concert to control a transcriptional regulatory network
that helps orchestrate mammalian embryogenesis as well
as the self-renewal and pluripotency of ES cells. Although
the full spectrum of genes regulated by Sox2 and Oct-3/4 is
only beginning to emerge, Sox2 and Oct-3/4 are known to
work cooperatively to stimulate the transcription of their
own genes and the transcription of a growing number of
downstream targets, many of which are required for
normal development. Previous studies have shed signiﬁ-
cant light into the mechanisms by which Sox2:Oct-3/4
target genes are activated (8–17). However, much less is
known about negative feedback controls that serve to
prevent the overexpression of these genes. The studies
described in this manuscript provide new insights into the
diversity of mechanisms used to tightly control transcrip-
tion of Sox2:Oct-3/4 target genes. Sox2 is a central player
in this control having a biphasic eﬀect on this network of
genes. Importantly, we demonstrate that overexpression
of Sox2 not only inhibits the activity of promoter/reporter
gene constructs for ﬁve diﬀerent Sox2:Oct-3/4 target
genes, but the endogenous expression of these genes is
inhibited within one day when Sox2 levels are elevated
 3-fold or less. In addition, our studies argue that
the inhibitory eﬀects of Sox2 are mediated through the
HMG/POU cassettes present in the enhancers of these
genes. Our studies further demonstrate that the region
containing the TAD of Sox2, and not the DBD, is
necessary for this inhibition. Lastly, the studies presented
here show that, unlike Sox2, overexpression of
neither Oct-3/4 nor Nanog exerts broad control over
Sox2:Oct-3/4 target genes.
Although overexpression of Sox2 exerts broad control
over Sox2:Oct-3/4 target genes, multiple lines of evidence
argue that the eﬀects of Sox2 overexpression are speciﬁc.
Moreover, Oct-3/4 and Nanog do not exert the same
broad-based inhibitory eﬀects observed with Sox2.
Importantly, our studies argue that Sox2 overexpression
does not exert a widespread repression of general
transcription. Sox2 overexpression did not inhibit several
viral promoters, including the CMV, SV40 or HSV TK
promoters. Similarly, Sox2 overexpression did not inhibit
the activities of Sox2 or FGF-4 promoter/reporter
constructs that lack their enhancers. In addition, pro-
moter/reporter gene constructs of these genes, in which the
HMG/POU cassettes were disrupted, were not inhibited.
In fact, they were stimulated by Sox2 overexpression.
Currently, it is unclear why Sox2 stimulated the mutant
promoter/reporter gene constructs. It is possible that
the stimulatory eﬀects of Sox2 are not speciﬁc.
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activity. (A) Eﬀect of Oct-3/4 overexpression on Oct-3/4 promoter
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particular gene construct. The data shown represents the mean and
standard deviation of duplicate samples from a representative experi-
ment. Each experiment was repeated twice and similar results were
obtained.
Nucleic Acids Research, 2007, Vol. 35, No. 6 1783Overexpression of Sox2 increases the basal activity of the
promoter-less parent construct several fold (data not
shown). However, the basal activity of the parent
construct is very low, and much lower than the activities
of our promoter/reporter gene constructs in which the
HMG/POU cassettes were disrupted. Moreover, previous
ﬁndings have shown that the cryptic activity within the
parent vector used in our studies is silenced when
promoters and strong enhancers, such as those used in
our studies, are inserted into the vector (35). Alternatively,
the regulatory regions inserted in our promoter/reporter
gene constructs may contain additional Sox2 response
elements. Previous studies have shown that the enhancer
present in our FGF-4 promoter/reporter gene construct
possesses a second functional HMG motif located  20bp
upstream of the HMG motif in the FGF-4 HMG/POU
cassette (46). However, disruption of this HMG motif in
conjunction with disruption of the HMG/POU cassette
did not ablate the stimulatory eﬀect observed with Sox2
overexpression. Further study will be needed to resolve
this question.
Our studies argue that the TAD of Sox2 is likely to be
responsible for its inhibitory action. Sox2 overexpression
may lead to the expression of a repressor that acts on
Sox2:Oct-3/4 target genes. Alternatively, Sox2 overexpres-
sion may interfere with the function of one or more
essential coactivators. Given that TADs activate tran-
scription by interacting with coactivators and are likely
to do so by interacting with more than one coactivator
(47–49), Sox2 overexpression may function by a
squelching mechanism (50), whereby incomplete
Sox2:cofactor complexes are generated that are unable
to activate Sox2:Oct-3/4 target genes. This model is similar
to one proposed to explain the inhibitory eﬀects observed
when overexpressing scaﬀold proteins (51). In the case
of Sox2, this seems likely given that it also physically
interacts with Oct-3/4 when bound to HMG/POU
cassettes (11,44,52). Currently very little is known about
the coactivators involved in the transcription of Sox2:Oct-
3/4 target genes. The one exception is p300 (13,30).
Previous studies have shown that p300 can mediate the
eﬀects of the GAL4-Sox2 fusion protein as well as the
combined eﬀects of Sox2 and Oct-3/4 on promoter/
reporter gene constructs (30). Moreover, ChIP studies
have shown that p300 is recruited to the FGF-4 enhancer
in F9 EC cells (13), and our unpublished studies indicate
that this is also true for the enhancer regions of the Nanog
gene and the Oct-3/4 gene where their HMG/POU
cassettes are located (Mallanna and Rizzino, unpublished
data). This prompted us to test whether overexpression
of p300 could reverse the inhibitory eﬀects of Sox2.
However, overexpression of p300 did not reverse the
inhibitory eﬀects of Sox2 (data not shown). Hence, Sox2
overexpression may inﬂuence the proper function of one
or more other coactivators.
An important outcome from the work described in this
study is the diﬀerence in the responses to overexpression
of Sox2, Oct-3/4 and Nanog (Figure 10). The response
to Sox2 is biphasic; whereas, the responses of most
Sox2:Oct-3/4 target genes to Oct-3/4 and Nanog are not.
At levels found in EC cells, Sox2 and Oct-3/4 activate
Sox2:Oct-3/4 target genes (Figure 10A). However, when
Sox2 levels rise, they begin to inhibit the expression
of Sox2:Oct-3/4 target genes (Figure 10B). Although
Sox2 exerts a general eﬀect over Sox2:Oct-3/4 target
genes, overexpression of Oct-3/4 or Nanog does not
(Figure 10C). Overexpression of Oct-3/4 inhibits
the activities of Oct-3/4 and Nanog promoter/reporter
gene constructs in EC cells, as it does in ES cells (27).
Normal levels (activation)
Elevated levels (repression)
Sox2
FGF-4
A
B
C
UTF1
Oct-3/4
Nanog
Sox2
FGF-4 UTF1
Oct-3/4
Nanog
Sox2
FGF-4 UTF1
Oct-3/4
Nanog
Figure 10. Model of Sox2, Oct-3/4 and Nanog feedforward and feed-
back gene regulation. Sox2 is shown as a central node in a network of
genes critical to embryogenesis as well as stem cell self-renewal and
pluripotency. (A) At normal levels, Sox2 and Oct-3/4 activate transcrip-
tion of all known Sox2:Oct-3/4 target genes. (B) Increasing levels of
Sox2 leads to inhibition of target gene expression. (C) Increasing levels
of Oct-3/4 inhibits expression of only Oct-3/4 and Nanog, and high
levels of Nanog lead to inhibition of Nanog gene expression, but not
other Sox2:Oct-3/4 target genes. Presumably, there are additional
Sox2:Oct-3/4 target genes that are regulated in a similar fashion.
1784 Nucleic Acids Research, 2007, Vol. 35, No. 6However, overexpression of Oct-3/4 slightly stimulates the
activities of Sox2 and FGF-4 promoter/reporter gene
constructs, rather than inhibiting them. Given the known
role of Oct-3/4 in the activation of the Sox2 and FGF-4
genes, this is not overly surprising. As is the case of
Oct-3/4, overexpression of Nanog leads to inhibition of its
own promoter (Figure 10C). Nonetheless, the failure of
Nanog to inhibit the Sox2 or the Oct-3/4 promoter/
reporter gene construct argues that overexpression of
Nanog does not exert a general restraining eﬀect over
Sox2:Oct-3/4 target genes.
In summary, the ﬁndings described in this study provide
new insights into the diversity of mechanisms used to
tightly control transcription of Sox2:Oct-3/4 target genes.
Importantly, our studies in conjunction with the large
number of earlier studies (8–17), which demonstrated the
role of Sox2 in the activation of Sox2:Oct-3/4 target genes,
argue that Sox2 functions as a molecular rheostat that
carefully controls a key transcriptional regulatory network
required for proper embryogenesis, as well as self-renewal
and pluripotency of ES and EC cells. Given our expanded
understanding of how Sox2 inﬂuences Sox2:Oct-3/4 target
genes, it will be important to examine more closely how
overexpression of Sox2 inﬂuences the growth and
diﬀerentiation of stem cells. In this regard, we did not
observe any phenotypic eﬀects of transient overexpression
of Sox2 in F9 EC cells. Interestingly, Sox2 overexpression
(2- to 20-fold increase in mRNA) has been shown to
promote the diﬀerentiation of ES cells into neuroecto-
derm, but it did not alter their ability to self-renew (53).
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